Shu‐Cheng Wan

1.1k total citations · 1 hit paper
23 papers, 913 citations indexed

About

Shu‐Cheng Wan is a scholar working on Biomedical Engineering, Molecular Biology and Oncology. According to data from OpenAlex, Shu‐Cheng Wan has authored 23 papers receiving a total of 913 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Biomedical Engineering, 11 papers in Molecular Biology and 9 papers in Oncology. Recurrent topics in Shu‐Cheng Wan's work include Nanoplatforms for cancer theranostics (11 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Inflammasome and immune disorders (4 papers). Shu‐Cheng Wan is often cited by papers focused on Nanoplatforms for cancer theranostics (11 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Inflammasome and immune disorders (4 papers). Shu‐Cheng Wan collaborates with scholars based in China, Hong Kong and Democratic Republic of the Congo. Shu‐Cheng Wan's co-authors include Zhi‐Jun Sun, Qi‐Chao Yang, Shuo Wang, Hexiang Deng, Liang Zhang, Yao Xiao, Leilei Yang, Zhi‐Zhong Wu, Jacky W. Y. Lam and Ben Zhong Tang and has published in prestigious journals such as Journal of the American Chemical Society, Advanced Materials and Nature Communications.

In The Last Decade

Shu‐Cheng Wan

23 papers receiving 908 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Integration of AIEgens into covalent organic frameworks for pyroptosis and ferroptosis primed cancer immunotherapy

2023 143 citations Liang Zhang, An Song et al. Nature Communications profile →

Peers

Countries citing papers authored by Shu‐Cheng Wan

Since Specialization

Citations

This map shows the geographic impact of Shu‐Cheng Wan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shu‐Cheng Wan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shu‐Cheng Wan more than expected).

Fields of papers citing papers by Shu‐Cheng Wan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shu‐Cheng Wan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shu‐Cheng Wan. The network helps show where Shu‐Cheng Wan may publish in the future.

Co-authorship network of co-authors of Shu‐Cheng Wan

This figure shows the co-authorship network connecting the top 25 collaborators of Shu‐Cheng Wan. A scholar is included among the top collaborators of Shu‐Cheng Wan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shu‐Cheng Wan. Shu‐Cheng Wan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Engineering Macrophage via Biomaterial-Mediated Mitochondrial Regulation: Mechanisms and Strategies 2025 ·Research ·(unknown), Minyu He, Shu‐Cheng Wan, Si Wang, (unknown), Liangjing Xin, Tao Chen	1
2	Enhanced sequential osteosarcoma therapy using a 3D-Printed bioceramic scaffold combined with 2D nanosheets via NIR-II photothermal-chemodynamic synergy 2025 ·Bioactive Materials ·(unknown), Si Wang, Xinlu Wang, Qinyi Lu, (unknown), Shu‐Cheng Wan, Shan Wang, Dize Li, (unknown), Qingqing He, Tao Chen, (unknown)	1
3	CTLA-4 blockade induces tumor pyroptosis via CD8+ T cells in head and neck squamous cell carcinoma 2023 ·Molecular Therapy ·Shuo Wang, Zhi‐Zhong Wu, (unknown), Shu‐Cheng Wan, Mengjie Zhang, Boxin Zhang, Qi‐Chao Yang, Yao Xiao, Hao Li, Liang Mao, Zhiyong Wang, J. Silvio Gutkind, Zhi‐Jun Sun	35
4	CSRP2 promotes cell stemness in head and neck squamous cell carcinoma 2023 ·Head & Neck ·(unknown), Jie Liu, Shu‐Cheng Wan, Jiaxing Li, Shuo Wang, (unknown), Cong‐Fa Huang, Zhi‐Jun Sun	6
5	Activation of Pyroptosis Using AIEgen-Based sp² Carbon-Linked Covalent Organic Frameworks 2023 ·Journal of the American Chemical Society ·Liang Zhang, Shu‐Cheng Wan, Jianyu Zhang, Mengjie Zhang, Qi‐Chao Yang, Boxin Zhang, Wuyin Wang, Jianwei Sun, Ryan T. K. Kwok, Jacky W. Y. Lam, Hexiang Deng, Zhi‐Jun Sun, Ben Zhong Tang	80
6	Integration of AIEgens into covalent organic frameworks for pyroptosis and ferroptosis primed cancer immunotherapy breakdown → 2023 ·Nature Communications ·Liang Zhang, An Song, Qi‐Chao Yang, Shu‐Jin Li, Shuo Wang, Shu‐Cheng Wan, Jianwei Sun, Ryan T. K. Kwok, Jacky W. Y. Lam, Hexiang Deng, Ben Zhong Tang, Zhi‐Jun Sun	143
7	CD103 blockade impair anti-CTLA-4 immunotherapy in oral cancer 2023 ·Oral Oncology ·Yao Xiao, (unknown), Qi‐Chao Yang, Shuo Wang, Zhi‐Zhong Wu, Shu‐Cheng Wan, Mengjie Zhang, Zhi‐Jun Sun	7
8	Targeting PCSK9 reduces cancer cell stemness and enhances antitumor immunity in head and neck cancer 2023 ·iScience ·Qi‐Chao Yang, Shuo Wang, Yuan‐Tong Liu, An Song, Zhi‐Zhong Wu, Shu‐Cheng Wan, Huimin Li, Zhi‐Jun Sun	15
9	Bioengineering of BRAF and COX2 inhibitor nanogels to boost the immunotherapy of melanomaviapyroptosis 2023 ·Chemical Communications ·Mengjie Zhang, Mengyun Liang, Shao‐Chen Yang, Xianbin Ma, Shu‐Cheng Wan, Qi‐Chao Yang, Shuo Wang, Zhigang Xu, Zhi‐Jun Sun	13
10	Engineered nanogels simultaneously implement HDAC inhibition and chemotherapy to boost antitumor immunity via pyroptosis 2022 ·Applied Materials Today ·(unknown), Yuan Gao, Yao Xiao, Shu‐Cheng Wan, Zhi‐Zhong Wu, Shuo Wang, Xianbin Ma, Zhigang Xu, Zhi‐Jun Sun	12
11	Staggered Stacking Covalent Organic Frameworks for Boosting Cancer Immunotherapy 2022 ·Advanced Functional Materials ·Liang Zhang, Yao Xiao, Qi‐Chao Yang, Leilei Yang, Shu‐Cheng Wan, Shuo Wang, Lu Zhang, Hexiang Deng, Zhi‐Jun Sun	77
12	NLRP3 in tumor-associated macrophages predicts a poor prognosis and promotes tumor growth in head and neck squamous cell carcinoma 2022 ·Cancer Immunology Immunotherapy ·Lei Chen, Shu‐Cheng Wan, Liang Mao, Cong‐Fa Huang, Lin‐Lin Bu, Zhi‐Jun Sun	17
13	pH-responsive nanoprodrugs combining a Src inhibitor and chemotherapy to potentiate antitumor immunity via pyroptosis in head and neck cancer 2022 ·Acta Biomaterialia ·(unknown), (unknown), Xianbin Ma, Zhi‐Zhong Wu, Shu‐Cheng Wan, Shao‐Chen Yang, Hao Li, Zhigang Xu, Zhi‐Jun Sun	25
14	Overexpression of CD168 is related to poor prognosis in oral squamous cell carcinoma 2021 ·Oral Diseases ·(unknown), Shuo Wang, Zhi‐Zhong Wu, Qi‐Chao Yang, (unknown), Shu‐Cheng Wan, Zhi‐Jun Sun	15
15	Engineering Multienzyme‐Mimicking Covalent Organic Frameworks as Pyroptosis Inducers for Boosting Antitumor Immunity 2021 ·Advanced Materials ·Liang Zhang, Qi‐Chao Yang, Shuo Wang, Yao Xiao, Shu‐Cheng Wan, Hexiang Deng, Zhi‐Jun Sun	159
16	Two‐Photon Absorption Induced Cancer Immunotherapy Using Covalent Organic Frameworks 2021 ·Advanced Functional Materials ·Leilei Yang, Liang Zhang, Shu‐Cheng Wan, Shuo Wang, Zhi‐Zhong Wu, Qi‐Chao Yang, Yao Xiao, Hexiang Deng, Zhi‐Jun Sun	58
17	Three-Dimensional Covalent Organic Frameworks with Cross-Linked Pores for Efficient Cancer Immunotherapy 2021 ·Nano Letters ·Liang Zhang, Leilei Yang, Shu‐Cheng Wan, Qi‐Chao Yang, Yao Xiao, Hexiang Deng, Zhi‐Jun Sun	57
18	Two‐Photon Absorption Induced Cancer Immunotherapy Using Covalent Organic Frameworks (Adv. Funct. Mater. 42/2021) 2021 ·Advanced Functional Materials ·Leilei Yang, Liang Zhang, Shu‐Cheng Wan, Shuo Wang, Zhi‐Zhong Wu, Qi‐Chao Yang, Yao Xiao, Hexiang Deng, Zhi‐Jun Sun	8
19	Overexpression of ATAD2 indicates Poor Prognosis in Oral Squamous Cell Carcinoma 2020 ·International Journal of Medical Sciences ·Xiaolong Wang, Shuo Wang, Zhi‐Zhong Wu, Qi‐Chao Yang, Hao Li, Hong‐Gang Xiong, Shu‐Cheng Wan, Zhi‐Jun Sun	12
20	Overexpression of PREX1 in oral squamous cell carcinoma indicates poor prognosis 2020 ·Journal of Molecular Histology ·Shu‐Cheng Wan, Hao Wu, Hao Li, Weiwei Deng, Yao Xiao, Cong‐Cong Wu, Leilei Yang, Wen‐Feng Zhang, Zhi‐Jun Sun	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact